Adult individuals with cervical cancer: 200 mg every 3 weeks or 400 mg every 6 weeks; administer Keytruda prior to chemotherapy with or without bevacizumab when given on the same day; until disease progression, unacceptable toxicity, or for Keytruda, up to 24 months Adult individuals with RCC: ...
In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years and older with early-stage triple-negative breast cancer. ...
This year’s San Antonio Breast Cancer Conference yielded major clinical updates on some of the hottest areas of oncology, from VEGF bispecifics that hope to challenge Merck’s Keytruda on efficacy to oral protein degraders that may offer patients more convenience. There were also a handful of ...
p_code_cip=&p_nom_commercial=KEYTRUDA&p_nb=2&p_site=AMELI&p_homol_retro=&p_homol_taa=taa(accessed on 20 February 2020). Herbst, R.S.; Baas, P.; Kim, D.-W.; Felip, E.; Pérez-Gracia, J.L.; Han, J.-Y.; Molina, J.; Kim, J.-H.; Arvis, C.D.; Ahn, M.-J.; ...